The company said, “Outset reiterated 2025 revenue guidance of $115 million to $125 million, and non-GAAP gross margin guidance in the high-30% range. Additionally, the company continues to expect to use less than $50 million of cash in 2025 as compared to the $103 million used in 2024.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- Positive Outlook for Outset Medical: Buy Rating and $15 Price Target Amid Share Adjustments and Market Trends
- Outset Medical price target adjusted to $15 at Stifel after reverse stock split
- Outset Medical trading resumes
- Outset Medical trading halted, volatility trading pause
- Outset Medical trading halted, news pending